FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2199941204> ?p ?o ?g. }

• W2199941204 endingPage "e1001932" @default.
• W2199941204 startingPage "e1001932" @default.
• W2199941204 abstract "For treating multidrug-resistant tuberculosis (MDR TB), the World Health Organization (WHO) recommends a regimen of at least four second-line drugs that are likely to be effective as well as pyrazinamide. WHO guidelines indicate only marginal benefit for regimens based directly on drug susceptibility testing (DST) results. Recent evidence from isolated cohorts suggests that regimens containing more drugs may be beneficial, and that DST results are predictive of regimen effectiveness. The objective of our study was to gain insight into how regimen design affects treatment response by analyzing the association between time to sputum culture conversion and both the number of potentially effective drugs included in a regimen and the DST results of the drugs in the regimen.We analyzed data from the Preserving Effective Tuberculosis Treatment Study (PETTS), a prospective observational study of 1,659 adults treated for MDR TB during 2005-2010 in nine countries: Estonia, Latvia, Peru, Philippines, Russian Federation, South Africa, South Korea, Thailand, and Taiwan. For all patients, monthly sputum samples were collected, and DST was performed on baseline isolates at the US Centers for Disease Control and Prevention. We included 1,137 patients in our analysis based on their having known baseline DST results for at least fluoroquinolones and second-line injectable drugs, and not having extensively drug-resistant TB. These patients were followed for a median of 20 mo (interquartile range 16-23 mo) after MDR TB treatment initiation. The primary outcome of interest was initial sputum culture conversion. We used Cox proportional hazards regression, stratifying by country to control for setting-associated confounders, and adjusting for the number of drugs to which patients' baseline isolates were resistant, baseline resistance pattern, previous treatment history, sputum smear result, and extent of disease on chest radiograph. In multivariable analysis, receiving an average of at least six potentially effective drugs (defined as drugs without a DST result indicating resistance) per day was associated with a 36% greater likelihood of sputum culture conversion than receiving an average of at least five but fewer than six potentially effective drugs per day (adjusted hazard ratio [aHR] 1.36, 95% CI 1.09-1.69). Inclusion of pyrazinamide (aHR 2.00, 95% CI 1.65-2.41) or more drugs to which baseline DST indicated susceptibility (aHR 1.65, 95% CI 1.48-1.84, per drug) in regimens was associated with greater increases in the likelihood of sputum culture conversion than including more drugs to which baseline DST indicated resistance (aHR 1.33, 95% CI 1.18-1.51, per drug). Including in the regimen more drugs for which DST was not performed was beneficial only if a minimum of three effective drugs was present in the regimen (aHR 1.39, 95% CI 1.09-1.76, per drug when three effective drugs present in regimen). The main limitation of this analysis is that it is based on observational data, not a randomized trial, and drug regimens varied across sites. However, PETTS was a uniquely large and rigorous observational study in terms of both the number of patients enrolled and the standardization of laboratory testing. Other limitations include the assumption of equivalent efficacy across drugs in a category, incomplete data on adherence, and the fact that the analysis considers only initial sputum culture conversion, not reversion or long-term relapse.MDR TB regimens including more potentially effective drugs than the minimum of five currently recommended by WHO may encourage improved response to treatment in patients with MDR TB. Rapid access to high-quality DST results could facilitate the design of more effective individualized regimens. Randomized controlled trials are necessary to confirm whether individualized regimens with more than five drugs can indeed achieve better cure rates than current recommended regimens." @default.
• W2199941204 created "2016-06-24" @default.
• W2199941204 creator A5001709140 @default.
• W2199941204 creator A5005460851 @default.
• W2199941204 creator A5010689312 @default.
• W2199941204 creator A5011112265 @default.
• W2199941204 creator A5016400476 @default.
• W2199941204 creator A5023107984 @default.
• W2199941204 creator A5024915830 @default.
• W2199941204 creator A5025087234 @default.
• W2199941204 creator A5026266435 @default.
• W2199941204 creator A5039644862 @default.
• W2199941204 creator A5049671547 @default.
• W2199941204 creator A5053266095 @default.
• W2199941204 creator A5053817241 @default.
• W2199941204 creator A5060693254 @default.
• W2199941204 creator A5061994881 @default.
• W2199941204 creator A5063418676 @default.
• W2199941204 creator A5066370166 @default.
• W2199941204 creator A5068801614 @default.
• W2199941204 creator A5071897207 @default.
• W2199941204 creator A5075880658 @default.
• W2199941204 creator A5081279738 @default.
• W2199941204 creator A5081289785 @default.
• W2199941204 date "2015-12-29" @default.
• W2199941204 modified "2023-10-02" @default.
• W2199941204 title "Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study" @default.
• W2199941204 cites W128341503 @default.
• W2199941204 cites W1966279006 @default.
• W2199941204 cites W1974647584 @default.
• W2199941204 cites W2007026404 @default.
• W2199941204 cites W2016436785 @default.
• W2199941204 cites W2024552105 @default.
• W2199941204 cites W2047186345 @default.
• W2199941204 cites W2125921446 @default.
• W2199941204 cites W2135027892 @default.
• W2199941204 cites W2140193283 @default.
• W2199941204 cites W2145441337 @default.
• W2199941204 cites W2145931216 @default.
• W2199941204 cites W2146416369 @default.
• W2199941204 cites W2153385258 @default.
• W2199941204 cites W2156941948 @default.
• W2199941204 cites W2164138449 @default.
• W2199941204 cites W2165192487 @default.
• W2199941204 cites W2167225727 @default.
• W2199941204 cites W2167629505 @default.
• W2199941204 cites W2171417449 @default.
• W2199941204 doi "https://doi.org/10.1371/journal.pmed.1001932" @default.
• W2199941204 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4700973" @default.
• W2199941204 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26714320" @default.
• W2199941204 hasPublicationYear "2015" @default.
• W2199941204 type Work @default.
• W2199941204 sameAs 2199941204 @default.
• W2199941204 citedByCount "37" @default.
• W2199941204 countsByYear W21999412042016 @default.
• W2199941204 countsByYear W21999412042017 @default.
• W2199941204 countsByYear W21999412042018 @default.
• W2199941204 countsByYear W21999412042019 @default.
• W2199941204 countsByYear W21999412042020 @default.
• W2199941204 countsByYear W21999412042021 @default.
• W2199941204 countsByYear W21999412042023 @default.
• W2199941204 crossrefType "journal-article" @default.
• W2199941204 hasAuthorship W2199941204A5001709140 @default.
• W2199941204 hasAuthorship W2199941204A5005460851 @default.
• W2199941204 hasAuthorship W2199941204A5010689312 @default.
• W2199941204 hasAuthorship W2199941204A5011112265 @default.
• W2199941204 hasAuthorship W2199941204A5016400476 @default.
• W2199941204 hasAuthorship W2199941204A5023107984 @default.
• W2199941204 hasAuthorship W2199941204A5024915830 @default.
• W2199941204 hasAuthorship W2199941204A5025087234 @default.
• W2199941204 hasAuthorship W2199941204A5026266435 @default.
• W2199941204 hasAuthorship W2199941204A5039644862 @default.
• W2199941204 hasAuthorship W2199941204A5049671547 @default.
• W2199941204 hasAuthorship W2199941204A5053266095 @default.
• W2199941204 hasAuthorship W2199941204A5053817241 @default.
• W2199941204 hasAuthorship W2199941204A5060693254 @default.
• W2199941204 hasAuthorship W2199941204A5061994881 @default.
• W2199941204 hasAuthorship W2199941204A5063418676 @default.
• W2199941204 hasAuthorship W2199941204A5066370166 @default.
• W2199941204 hasAuthorship W2199941204A5068801614 @default.
• W2199941204 hasAuthorship W2199941204A5071897207 @default.
• W2199941204 hasAuthorship W2199941204A5075880658 @default.
• W2199941204 hasAuthorship W2199941204A5081279738 @default.
• W2199941204 hasAuthorship W2199941204A5081289785 @default.
• W2199941204 hasBestOaLocation W21999412041 @default.
• W2199941204 hasConcept C119060515 @default.
• W2199941204 hasConcept C126322002 @default.
• W2199941204 hasConcept C142724271 @default.
• W2199941204 hasConcept C188816634 @default.
• W2199941204 hasConcept C2776301714 @default.
• W2199941204 hasConcept C2777107064 @default.
• W2199941204 hasConcept C2777768864 @default.
• W2199941204 hasConcept C2777975735 @default.
• W2199941204 hasConcept C2779912665 @default.
• W2199941204 hasConcept C2780459521 @default.
• W2199941204 hasConcept C2781069245 @default.
• W2199941204 hasConcept C2781413609 @default.
• W2199941204 hasConcept C50382708 @default.

• next